We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > lumateperone

News List

Intra-Cellular Therapies Announces Positive Results from Bipolar Depression Treatment Study americanpharmaceuticalreview
September 14, 2020
Intra-Cellular Therapies announced positive topline results from its Phase 3 clinical trial (Study 402) evaluating lumateperone as adjunctive therapy to lithium or valproate in the treatment of major depressive episodes associated with Bipolar I or ...
Intra-Cellular Therapies Provides Lumateperone Regulatory Update drugs
September 16, 2019
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders ...
Intra-Cellular Therapies Announces Positive Phase III Results contractpharma
July 17, 2019
Lumateperone achieves topline results in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder.